NU Skin Enterprises Inc

NU Skin Enterprises Inc (NUS) Stock Analysis

$4.990

+0.308 (+6.17%)At close

Loading chart…
High
5.130
Open
4.830
VWAP
4.98
Volume
646.13K
Mkt Cap
536.41M
Low
4.830
Amount
3.22M
EV/EBITDA, TTM
2.16

Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its beauty & skincare solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lines and wrinkles, and oily skin and pores. Its health & wellness solutions include gut health, bone and joint health, brain health, energy and stamina, heart health, immunity support, and protein and fitness. It offers various beauty devices, including ageLOC LumiSpa, Nu Skin RenuSpa iO and Prysm iO. Its ageLOC LumiSpa includes products such as LumiSpa iO Superpower Kit, ageLOC Rose Gold LumiSpa iO, LumiSpa Rose Gold Accent Twin Pack, and others.

AI analysis of NU Skin Enterprises Inc (NUS)

Buy

NU Skin Enterprises Inc (NUS) is a good buy right now, trading at $4.78, which is significantly below its 52-week high of $11.67. The forward P/E ratio is 4.008, indicating potential undervaluation compared to future earnings. Additionally, the stock has shown a recent positive trend with a 5-day change of +1.92% and a 20-day change of +3.24%. However, a key risk is the net margin, which has dropped to -78.03% in Q2 2026, indicating potential ongoing profitability issues that investors should monitor closely.

Analyst Ratings (6)

Buy
3 Buy
1 Hold
2 Sell
Current: 4.99
Low
—
Average
—
High
—

DA Davidson

2024-12-20

Price Target

$7

Hold

Citigroup

2024-10-22

Price Target

$6.75

Hold

DA Davidson

2024-08-12

Price Target

$11

Hold

Citigroup

2024-08-09

Price Target

$12

Hold

DA Davidson

2024-05-09

Price Target

$13

Hold

Valuation Metrics

The current forward P/E ratio for NU Skin Enterprises Inc (NUS) is 4.12, compared to its 5-year average forward P/E of 11.03.

Forward P/E

Undervalued
5Y Average P/E
11.03
Current P/E
4.12
Overvalued
16.12
Undervalued
5.93

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
5.36
Current EV/EBITDA
2.16
Overvalued
8.39
Undervalued
2.34

Forward P/S

Undervalued
5Y Average P/S
0.51
Current P/S
0.16
Overvalued
0.84
Undervalued
0.18

Alphio AI Price Scenarios for NUS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%NUS

$6.63

Scenario price

B

Base

Base · 50%NUS

$6.29

Scenario price

B

Bear

Bear · 25%NUS

$4.75

Scenario price

Whales holding NUS

C

Castleknight Management LP

+ HoldingNUS

-5.48%

3M Return

Events Timeline

2026-08-10 (ET)

16:30:00

Cuts FY26 Revenue View to $1.28B-$1.35B

16:30:00

Sees Q3 Revenue of $310M to $340M

2026-05-07 (ET)

16:10:00

Sees Q2 Revenue of $330M-$360M

16:10:00

Nu Skin Q1 Revenue at $320.6M, Below Estimate

16:10:00

Company Confirms FY26 Revenue Outlook of $1.35B to $1.5B

News

NUS FAQ — answered by Alphio AI

Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its beauty & skincare solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lines and wrinkles, and oily skin and pores. Its health & wellness solutions include gut health, bone and joint health, brain health, energy and stamina, heart health, immunity support, and protein and fitness. It offers various beauty devices, including ageLOC LumiSpa, Nu Skin RenuSpa iO and Prysm iO. Its ageLOC LumiSpa includes products such as LumiSpa iO Superpower Kit, ageLOC Rose Gold LumiSpa iO, LumiSpa Rose Gold Accent Twin Pack, and others. It operates in the Consumer Non-Cyclicals sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

NU Skin Enterprises Inc (NUS) is a good buy right now, trading at $4.78, which is significantly below its 52-week high of $11.67. The forward P/E ratio is 4.008, indicating potential undervaluation compared to future earnings. Additionally, the stock has shown a recent positive trend with a 5-day change of +1.92% and a 20-day change of +3.24%. However, a key risk is the net margin, which has dropped to -78.03% in Q2 2026, indicating potential ongoing profitability issues that investors should monitor closely.

6 analysts cover NUS: 3 rate it Buy, 1 Hold and 2 Sell.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading